Lilly hires ‘powerhouse’ D.C. lobbyist
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Pharmaceutical
Articles
Lilly migraine drug provides relief in late-stage trials
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
Drug lobby mulling membership reductions amid price scrutiny
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
Marsh Supermarkets closing all in-store pharmacies
The struggling grocery chain told employees Friday morning that it plans to discontinue pharmacy operations and has sold customer prescription files to a national drug store chain.
Express Scripts rebounds as Anthem holds out hope of reconciliation
Express Scripts Holding Co. shares rose Wednesday after health insurer Anthem Inc., its biggest client, said it hasn’t ruled out using the pharmacy benefit manager after their contract expires.
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Express Scripts expects to be dumped by Anthem after 2019
The prescription drug manager said Indianapolis-based Anthem Inc., its biggest customer, doesn’t plan to extend its contract when it expires even though Express Scripts is offering major discounts.
Local life sciences, pharma consultancy acquired by German firm
Safis Solutions LLC, a 15-year-old Indianapolis consulting firm that helps life science companies move their products through the government regulatory process, has been acquired by PharmaLex, the companies announced Monday.
Wall Street punishes Lilly for latest drug setback; analysts grasp for answers
News that federal regulators rejected Lilly’s drug for arthritis sent the stock tumbling more than 5 percent Monday, and sent surprised analysts searching for answers.
Lilly’s rheumatoid arthritis pill rejected by regulators
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
FDA issues warning to local doctor for breaking protocol on drug trial
The federal agency says the Indianapolis doctor studying Pfizer’s Chantix last year failed to keep accurate records and used patients who didn’t meet the trial requirements.
Blame game over drug prices escalates with new ad campaign
Broadening its efforts to defuse outrage over skyrocketing prices, the pharmaceutical industry’s lobbying association has started an advertising campaign urging insurers to share with customers more of the benefits of rebates they’ve negotiated.
Eli Lilly chasing psoriasis jackpot with Taltz
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Pharma stocks slide after new tweet from Trump on drug prices
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Indy-founded drug firm lands nearly $23M to fight rare disease
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
Dying patients have Pence’s backing on ‘right to try’ policy
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
UPDATE: Trump tells drugmakers, including Lilly, their prices are ‘astronomical’
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
Carmel biotech firm scores major deal with pharmaceutical giant
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.